Who
Johanna Friedl-Naderer
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Dyne Therapeutics; EVP & Chief Operating Officer, Vir Biotechnology.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $135K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Mar 2022
- Last trade
- 8 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,493185 at $18.88 | filing |
| 8 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,493185 at $18.88 | filing |
| 4 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K900 at $24.35 | filing |
| 4 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K900 at $24.35 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,939226 at $26.28 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,939226 at $26.28 | filing |
| 16 Jun 2026filed 17 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,658145 at $18.33 | filing |
| 16 Jun 2026filed 17 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,658145 at $18.33 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,186228 at $18.36 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,186228 at $18.36 | filing |
| 5 Mar 2026filed 6 Mar 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,205148 at $14.90 | filing |
| 5 Mar 2026filed 6 Mar 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,205148 at $14.90 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Dec 2025filed 5 Dec 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,984144 at $20.72 | filing |
| 5 Sep 2025filed 8 Sep 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,931144 at $13.41 | filing |
| 4 Sep 2025filed 8 Sep 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K894 at $13.27 | filing |
| 16 Jul 2025filed 18 Jul 2025 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,255 at $0.00 | filing |
News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)DYN · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Johanna Friedl-Naderer; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.